姓名：陈文明 性别：男 职称：主任医师、教授 招生院所：附属朝阳医院 招生类型：科学与专业学位(博) 科学与专业学位(硕) 招生专业：内科学（血液病）(博) 内科学（血液病）(硕) 研究方向名称：多发性骨髓瘤基础与临床 电子信箱：**@163.com


社会任职
1. 中国医药教育协会血液学专业委员会主任委员
2. 中国抗癌协会血液肿瘤分会常委
3. 亚洲骨髓瘤王（AMN）常委
4. 中华医学会血液分会造血干细胞应用学组成员
5. 中国医师协会血液科医师分会委员、骨髓瘤专家委员会副主任
6. 中国中西医结合学会血液分会常委骨髓瘤专委会副主委
7. 中国免疫学会血液免疫分会常委
个人简历
1. 198409-198906:武汉大学医学部 学习
2. 198602-198607:上海医科大学 学习
3. 198907-:北京朝阳医院 工作
4. 198908-199411:北京朝阳医院 住院医师
5. 199209-199212:南开大学医学院 学习
6. 199309-199706:首都医科大学 学习
7. 199412-199911:北京朝阳医院 主治医师
8. 199911-200110:法国Rouen大学 学习
9. 199912-200411:北京朝阳医院 副主任医师
10. 200411-:北京朝阳医院 主任医师
重要学术论文
1. Hu Y, et al.Progress in the identification of gene mutations involved in multiple myeloma . OncoTargets and Therapy . 2019,12: 4075–4080 .SCI
2. Zhang ZY.Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma . Biomed Research International . 2019,【未填写卷（期）】:10.1155/2019/** .SCI
3. Chen WM, et al.1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China. ONCOLOGIST. 2019,24(11) : e1132-e1140 .SCI
4. Lu MQ, et al..Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. . BMC Medical Genomics . 2019,12(1) : 135-150 .SCI
5. Zhang ZY, et al..Serum exosomal microRNAs as novel biomarkers for multiple myeloma. HEMATOLOGICAL ONCOLOGY . 2019,37(4) :409-417 .
6. Jia J, Wang H, Wu M, Zhang F, Liu X, Chen W, Liu A.Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib:A Case Report and Review of the Literature. ACTAHAEMATOLOGICA. 2018,140(1):46-50.SCI
7. Gao W, Li J, Jian Y, Yang G, Wu Y, Li Y, Len Y, Liu A, Tian Y, Wang H, Zhou H, Zhang Z, Chen W.Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy,but not ASCT consolidation. INTERNATIONAL JOURNAL OF HEMATOLOGY. 2018,epub:epub.SCI
8. Zhang Z, Li Z, Chen W.Down-regulated G protein-coupled receptor kinase 6 leads to apoptosis in multiple myelomaMM1R cells. Experimental and Therapeutic Medicine. 2018,16(5):4253-4259.SCI
9. Tian Y, Zhang Y, Zhu WQ, Chen XL, Zhou HB, Chen WM.Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma. Biomed Research International. 2018,2018:**.SCI
10. YinWu，Giaisi M, Köhler R, Krammer PH, Chen WM, Li-Weber M..Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model. . Cancer Letters. 2017,389 :70-77.SCI
11. Gao W, Guo WJ, Hou DY, Yang GZ, Wu Y, Li YC, Leng Y, Tang Y, Xu L, Liu JM,Wang H, Wang X, Zhang J, Zhao WS, Zhang L..Autoantibodies against β(1)-adrenergic receptor: response to induction therapy with bortezomib-containing regimens for multiple myeloma patients.. Leuk Lymphoma.. 2017,59（3）:717-724 .SCI
12. Leng Y, Hou J, Jin J, Zhang M, Ke X, Jiang B, Pan L, Yang L, Zhou F, Wang J,Wang Z, Liu L, Li W, Shen Z, Qiu L, Chang N, Li J, Liu J, Pang H, Meng H, Wei P, Jiang H, Liu Y, Zheng X, Yang S.Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/ refractory multiple myeloma: a phase 2 study.. Cancer Chemother Pharmacol. 2017,79（6）:1141-1149 .SCI
13. Zhou H，Jian Y, Chen W.Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.. INT J HEMATOL. 2017,105（3）:318-325 .SCI
14. Leng Y, Qiu L, Hou J, Zhao Y, Zhang X, Yang S, Xi H, Huang Z, Pan L, Chen W.. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma.. Chin J Cancer.. 2016,35(1) :86.SCI
15. 指南.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.. Ann Oncol. 2016,28(2):228-245.SCI
16. Geng C, Hou J, Zhao Y, Ke X, Wang Z, Qiu L, Xi H, Wang F, Wei N, Liu Y, Yang S, Wei P, Zheng X, Huang Z, Zhu B,Chen W.A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.. Am J Hematol. 2016,89(11):1037-42..SCI
17. 指南.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.. Lancet Oncol. 2016,17(8):e328-e346.SCI
18. Wang G. Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival . ACTA HAEMATOL-BASEL . 2016,136(3) :140-146.SCI
19. Zhu W,Chen WM.Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.. Medicine (Baltimore). 2016,95(46) :e5202 .
20. Yan D1, Wei P, An G, Chen W.Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg. 2013,8:149.SCI
21. Gao W, Geng C, Zhang L, Li Y, Chen W, Wang C.Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction. Hematology. 2013,18(6):341-7.SCI
22. Geng CY1, Liu N, Yang GZ, Liu AJ, Leng Y, Wang HJ, Li LH, Wu Y, Li YC, Chen WM..Differential protein expression profile between CD20 positive and negative cells of the NCI-H929 cell line. Asian Pac J Cancer Prev . 2012,13(11):5409-13 .SCI
23. Dispenzieri A, Kyle R, Merlini G,... Chen W, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009,23(2):215-24.SCI
主编或副主编的著作/译著
1. 《贝塞斯达临床血液学手册》,主编,北京大学医学出版社,201801
2. 《临床血液与检验学 》,主编,科学出版社 ,201701
3. 《多发性骨髓瘤的护理与管理 》,主编,人民卫生出版社 ,20170
4. 《多发性骨髓瘤骨病外科治疗》,主编,人民卫生出版社,2014
5. 《血液病学》,主编,科学出版社,201206
6. 《多发性骨髓瘤--现状与进展》,主编,人民军医出版社,201005
7.
8.
9.
10.
重要奖项
1. 北京市卫生局科技成果奖 一等，1 199908
2. 国家教育部科技进步奖 二等，12 199901
3. 北京市卫生局科技成果奖 二等，2 199609